Real-World Analysis of Healthcare Utilization, Treatment Patterns, and Economic Burden in Medicare Beneficiaries with Parkinson’s Disease: Implications by Levodopa Formulation and Disease Severity
This study provides comprehensive real-world evidence on carbidopa-levodopa use in Medicare beneficiaries with PD. Findings highlight the need for individualized treatment approaches, considering both symptom control and healthcare costs. Future research should focus on prospective studies to assess long-term outcomes and economic impact of different treatment strategies in PD, considering disease severity and quality of life.
Authors
- Kimberly J. Martin (ORCID: https://orcid.org/0000-0002-8350-6407)
- Winona Tse (ORCID: https://orcid.org/0000-0002-8527-0936)
- Renée J.G. Arnold (ORCID: https://orcid.org/0000-0001-5935-3220)
- Renee Kuan
Institutions
- Oregon Health & Science University (US)
- University of Colorado Boulder (US)
- Arnold Ventures (US)
- Boulder Language Technologies (United States) (US)
- National Heart, Lung, and Blood Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1007/s41669-025-00588-w
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amneal Pharmaceuticals